Drug sensitivity and synergy in patient-derived organoids was consistent with our results in established PDAC cell culture models (Fig. 6a-d), suggesting that combination targeting of DHODH and BCL-XL may inhibit tumor growth in tumor models of PDAC. This evidence concerns the gene BCL2L1 and neoplasm.